Literature DB >> 10235581

Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma.

B C Vrouenraets1, G A Hart, A M Eggermont, J M Klaase, B N van Geel, O E Nieweg, B B Kroon.   

Abstract

BACKGROUND: The optimal toxic reaction of the normal tissues in perfused limbs after isolated limb perfusion (ILP) is unknown. Theoretically, more severe limb toxicity could reflect a concomitant increased toxic effect to the tumor and improved outcomes. We determined whether there is a relation between limb toxicity and treatment outcomes after ILP for recurrent limb melanoma. STUDY
DESIGN: Among 252 patients with recurrent melanoma of the limbs, treatment outcomes in 192 patients (76%) with no or mild acute limb toxicity were compared with those in 60 (24%) with more severe reactions. Multivariate analysis was used to identify prognostic factors for complete response, limb recurrence-free interval, and survival.
RESULTS: Among 112 patients with measurable disease, 65 patients (58%) had a complete response and 27 (42%) experienced a relapse in the perfused limb. For complete response, uninvolved regional lymph nodes (p = 0.0025) and ILP using tumor necrosis factor-alpha (p = 0.0076) appeared to be favorable prognostic factors in multivariate analysis. There was no evidence of a relation between limb toxicity and complete response either in univariate (p = 0.16) or multivariate analysis (p = 0.46). For limb recurrent-free interval, only the number of lesions was a significant prognostic factor (p = 0.047); limb toxicity was not (p = 0.095). In 140 patients with recurrent melanoma excised before or at the moment of ILP, independent prognostic factors for survival were gender, the number of positive nodes, and stage of disease. There was no relation between limb toxicity and survival in either univariate (p = 0.53) or multivariate analysis (p = 0.94). Forty-eight (34%) of the 140 patients had a relapse in the perfused limb. No prognostic factors for limb recurrent-free interval could be identified; limb toxicity was not related to relapse time in univariate or multivariate analyses (p = 0.16 and p = 0.14, respectively).
CONCLUSIONS: More severe acute limb toxicity is not associated with improved outcomes. One should aim at grade II toxicity (slight erythema or edema, compatible with complete recovery) at the most to increase the therapeutic ratio of ILP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235581     DOI: 10.1016/s1072-7515(99)00018-6

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  10 in total

Review 1.  Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.

Authors:  David Moreno-Ramirez; Luis de la Cruz-Merino; Lara Ferrandiz; Roman Villegas-Portero; Adoracion Nieto-Garcia
Journal:  Oncologist       Date:  2010-03-26

Review 2.  Regional treatment strategies for in-transit melanoma metastasis.

Authors:  Ryan S Turley; Amanda K Raymond; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2011-01       Impact factor: 3.495

Review 3.  Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.

Authors:  Douglas B Johnson; Igor Puzanov; Mark C Kelley
Journal:  Immunotherapy       Date:  2015-06-22       Impact factor: 4.196

4.  One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Authors:  Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 5.  Optimizing regional infusion treatment strategies for melanoma of the extremities.

Authors:  Andrew Coleman; Christina K Augustine; Georgia Beasley; Gretchen Sanders; Douglas Tyler
Journal:  Expert Rev Anticancer Ther       Date:  2009-11       Impact factor: 4.512

6.  20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.

Authors:  Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Johannes H W de Wilt; Jacobus W A Burger; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

7.  Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity.

Authors:  João Pedreira Duprat Neto; Fernanda Oliveira; Eduardo Bertolli; Andre Sapata Molina; Kenji Nishinari; Luciana Facure; Jose Humberto Fregnani
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

8.  Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.

Authors:  J F Thompson; G A Siebert; Y G Anissimov; B M Smithers; A Doubrovsky; C D Anderson; M S Roberts
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

Review 9.  Management of in-transit melanoma of the extremity with isolated limb perfusion.

Authors:  Douglas L Fraker
Journal:  Curr Treat Options Oncol       Date:  2004-06

Review 10.  Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma.

Authors:  Pier Francesco Ferrucci; Laura Pala; Fabio Conforti; Emilia Cocorocchio
Journal:  Cancers (Basel)       Date:  2021-03-18       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.